These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24996451)

  • 1. Predictive factors for recovery time in patients suffering from severe OHSS.
    Nouri K; Tempfer CB; Lenart C; Windischbauer L; Walch K; Promberger R; Ott J
    Reprod Biol Endocrinol; 2014 Jul; 12():59. PubMed ID: 24996451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Factors for Recovery Time in Conceived Women Suffering From Moderate to Severe Ovarian Hyperstimulation Syndrome.
    Huang K; Shi Y; Chen G; Shi H; Zhai J
    Front Endocrinol (Lausanne); 2022; 13():870008. PubMed ID: 35784536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe ovarian hyperstimulation syndrome modifies early maternal serum beta-human chorionic gonadotropin kinetics, but obstetrical and neonatal outcomes are not impacted.
    Choux C; Barberet J; Ginod P; Cottenet J; Bruno C; Benzénine E; Sagot P; Fauque P
    Fertil Steril; 2017 Oct; 108(4):650-658.e2. PubMed ID: 28911926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
    Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
    Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on ovarian hyperstimulation syndrome: part 2--clinical signs and treatment.
    Binder H; Dittrich R; Einhaust F; Krieg J; Müller A; Strauss R; Beckmann MW; Cupisti S
    Int J Fertil Womens Med; 2007; 52(2-3):69-81. PubMed ID: 18320864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
    O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
    J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Ross R; Morris S
    Fertil Steril; 2005 Jul; 84(1):93-8. PubMed ID: 16009163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of repeated abdominal paracentesis on uterine and intraovarian haemodynamics and pregnancy outcome in severe ovarian hyperstimulation syndrome.
    Chen CD; Yang JH; Chao KH; Chen SU; Ho HN; Yang YS
    Hum Reprod; 1998 Aug; 13(8):2077-81. PubMed ID: 9756272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein response is higher in early than in late ovarian hyperstimulation syndrome.
    Korhonen KV; Savolainen-Peltonen HM; Mikkola TS; Tiitinen AE; Unkila-Kallio LS
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():162-168. PubMed ID: 27865939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk.
    Gao R; Liao X; Huang W; Zeng R; Qin L; Bai P
    Front Endocrinol (Lausanne); 2022; 13():905263. PubMed ID: 35757417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistent hemoconcentration and hypoosmolality during superovulation and in severe ovarian hyperstimulation syndrome: a volume homeostasis paradox.
    Evbuomwan IO; Davison JM; Murdoch AP
    Fertil Steril; 2000 Jul; 74(1):67-72. PubMed ID: 10899499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and laboratory evaluation of hospitalized patients with severe ovarian hyperstimulation syndrome.
    Cunha-Filho JS; Samama M; Fanchin R; Righini C; Kadoch IJ; Frydman R; Olivennes F
    Reprod Biomed Online; 2003 Jun; 6(4):448-51. PubMed ID: 12831592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.